Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

X
Trial Profile

A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serdexmethylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms Laboratory Classroom Study
  • Sponsors KemPharm; Zevra Therapeutics
  • Most Recent Events

    • 13 Mar 2023 According to a Corium media release, data from this study will be presented in at the American Neuropsychiatric Association (ANPA) 2023 meeting on Wednesday, March 15, from 5:30 to 7:00 p.m. EDT. in Staffordshire Room of the Westin at Copley Place in Boston, MA.
    • 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
    • 13 Sep 2022 According to a Corium International media release, data from this study will be presented in upcoming Psych Congress 2022; Coriums Psych Congress 2022 posters will be presented on Sunday, September 18, and Monday, September 19, from 1:30 to 3:00 pm CDT (2:30 to 4:00 pm EDT) in Hall D of the New Orleans Convention Center.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top